Arcus Biosciences (RCUS) EBITDA Margin (2017 - 2026)

Arcus Biosciences' EBITDA Margin history runs 10 years deep, the most recent figure standing at 788.24% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 35252.0% year-over-year to 788.24% in Q1 2026; TTM through Mar 2026 was 168.64%, a 14058.0% increase from a year earlier, with the FY2025 full-year figure at 156.28%, down 2837.0% from the prior year.
• EBITDA Margin declined to 788.24% in Q1 2026 per RCUS's latest filing, from 345.45% in the prior quarter.
• Across five years, EBITDA Margin topped out at 5.0% in Q2 2025 and bottomed at 788.24% in Q1 2026.
• The 5-year median for EBITDA Margin is 286.21% (2023), against an average of 329.77%.
• Across the five-year window, EBITDA Margin surged 61375 bps in 2022 and sank 43235 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 217.65% in 2022, then plunged by 199 bps to 650.0% in 2023, then surged by 39 bps to 396.15% in 2024, then advanced by 13 bps to 345.45% in 2025, then sank by 128 bps to 788.24% in 2026.
• Per Business Quant, the three latest RCUS EBITDA Margin figures stand at 788.24% (Q1 2026), 345.45% (Q4 2025), and 546.15% (Q3 2025).